3,041 Shares in Cencora, Inc. $COR Purchased by Krilogy Financial LLC

Krilogy Financial LLC acquired a new position in shares of Cencora, Inc. (NYSE:COR) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 3,041 shares of the company’s stock, valued at approximately $913,000.

Other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new position in shares of Cencora during the second quarter valued at $5,154,136,000. T. Rowe Price Investment Management Inc. grew its position in shares of Cencora by 160.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 6,700,091 shares of the company’s stock worth $2,262,956,000 after acquiring an additional 4,123,795 shares during the last quarter. Bank of America Corp DE increased its holdings in shares of Cencora by 6.9% in the 1st quarter. Bank of America Corp DE now owns 4,138,388 shares of the company’s stock worth $1,300,033,000 after acquiring an additional 267,318 shares during the period. Amundi increased its holdings in shares of Cencora by 43.5% in the 2nd quarter. Amundi now owns 2,229,326 shares of the company’s stock worth $630,855,000 after acquiring an additional 676,066 shares during the period. Finally, Carmignac Gestion increased its holdings in shares of Cencora by 58.7% in the 2nd quarter. Carmignac Gestion now owns 1,747,363 shares of the company’s stock worth $494,463,000 after acquiring an additional 646,112 shares during the period. 97.52% of the stock is owned by institutional investors and hedge funds.

Cencora Price Performance

COR traded down $0.87 on Friday, reaching $340.54. The company had a trading volume of 1,978,868 shares, compared to its average volume of 1,282,490. The company has a market capitalization of $64.99 billion, a P/E ratio of 25.30, a PEG ratio of 1.75 and a beta of 0.58. The company has a current ratio of 0.93, a quick ratio of 0.58 and a debt-to-equity ratio of 3.53. The company has a fifty day moving average of $320.38 and a 200-day moving average of $303.34. Cencora, Inc. has a one year low of $244.82 and a one year high of $377.54.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, August 5th. The company reported $4.48 EPS for the quarter, topping analysts’ consensus estimates of $4.35 by $0.13. The company had revenue of $84.75 billion for the quarter, compared to the consensus estimate of $84.31 billion. Cencora had a net margin of 0.79% and a return on equity of 125.45%. Cencora’s revenue was up 5.1% on a year-over-year basis. During the same period in the previous year, the firm earned $4.00 EPS. As a group, equities research analysts anticipate that Cencora, Inc. will post 17.87 earnings per share for the current year.

Cencora Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Friday, August 14th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date was Friday, August 14th. Cencora’s dividend payout ratio is 17.83%.

Analyst Ratings Changes

COR has been the topic of several recent research reports. Robert W. Baird boosted their target price on shares of Cencora from $370.00 to $373.00 and gave the company an “outperform” rating in a research note on Monday, October 12th. Citigroup restated a “buy” rating on shares of Cencora in a research report on Thursday, August 6th. Evercore restated an “outperform” rating and issued a $350.00 price target (up from $330.00) on shares of Cencora in a research note on Thursday, August 6th. Wells Fargo & Company lifted their price target on Cencora from $331.00 to $395.00 and gave the company an “overweight” rating in a report on Tuesday, August 11th. Finally, Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. Fourteen equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $363.81.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth Campbell sold 11,300 shares of the stock in a transaction on Monday, August 24th. The stock was sold at an average price of $324.12, for a total transaction of $3,662,556.00. Following the completion of the transaction, the executive vice president directly owned 19,455 shares of the company’s stock, valued at approximately $6,305,754.60. This trade represents a 36.74% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.38% of the stock is owned by company insiders.

Cencora Profile

Cencora, formerly known as AmerisourceBergen, is a global pharmaceutical solutions company that sources, distributes and supports the delivery of medicines and healthcare products. The company serves pharmaceutical manufacturers, healthcare providers, pharmacies and animal-health customers through its supply-chain and commercialization services.

Its activities include pharmaceutical and specialty-product distribution, manufacturer services, specialty logistics, clinical-trial support, patient-support programs and other services designed to help bring medicines to market and improve access to treatment.